Sangamo Therapeutics, Inc.
NASDAQ:SGMOBiotechnology
Healthcare
$0.18 +2.06%
+$0.00 today
- Market cap
- $70.43M
- Beta
- 1.29
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$0.32
52W Low $0.10High $0.77
Volume 0.61M
Average 9.53M
Income Statement
Follow revenue through to earnings.
Revenue
$39.55M
FY 2025 · Annual
-31.6% YoYOperating Income
-$108.00M
FY 2025 · Annual
Net Income
-$122.93M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 110.7M | 111.3M | 176.23M | 57.8M | 39.55M |
| Cost of Revenue | 0 | 12.11M | 0 | 0 | 7.6M |
| Gross Profit | 110.7M | 99.19M | 176.23M | 57.8M | 31.95M |
| Gross Margin | 100.0% | 89.1% | 100.0% | 100.0% | 80.8% |
| Research & Development | 230.82M | 249.9M | 234.06M | 111.52M | 112.67M |
| Selling, General & Admin | 63.22M | 62.68M | 61.17M | 44.73M | 34.89M |
| Operating Expenses | 294.04M | 300.47M | 450.24M | 161.77M | 139.95M |
| Depreciation & Amortization | 17.64M | 12.11M | 22.19M | 9.36M | 7.6M |
| EBITDA | (160.35M) | (179.74M) | (96.8M) | (89.09M) | (115.9M) |
| EBITDA Margin | -144.9% | -161.5% | -54.9% | -154.1% | -293.0% |
| Operating Income | (183.34M) | (201.28M) | (274.01M) | (103.97M) | (108M) |
| Operating Margin | -165.6% | -180.8% | -155.5% | -179.9% | -273.1% |
| Interest Income | 5.35M | 9.43M | 11.1M | 5.86M | 1.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 5.35M | 9.43M | 11.1M | 5.86M | (15.5M) |
| Income Before Tax | (177.99M) | (191.85M) | (262.9M) | (98.11M) | (123.5M) |
| Pre-Tax Margin | -160.8% | -172.4% | -149.2% | -169.7% | -312.2% |
| Income Tax Expense | 306K | 429K | (5.07M) | (167K) | (568K) |
| Net Income | (178.29M) | (192.28M) | (257.83M) | (97.94M) | (122.93M) |
| Net Margin | -161.1% | -172.8% | -146.3% | -169.4% | -310.8% |
| EPS (Basic) | (1.23) | (1.25) | (1.48) | (0.49) | (0.44) |
| EPS (Diluted) | (1.23) | (1.25) | (1.48) | (0.49) | (0.44) |
| 144.57M | 154.35M | 174.44M | 201.7M | 280.19M | |
| 144.57M | 154.35M | 174.44M | 201.7M | 280.19M |
SGMO Earnings Waterfall · TTM
NASDAQ:SGMO · Revenue to Net Income
Key Ratios
EPS$-0.38
Gross Margin100.0%
Net Margin-2133.4%
P/E Ratio-1.2
P/S Ratio109.2
Analysis
$34.6M of revenue converted into -$123.3M of net income for the selected period. Gross margin is 100.0% and net margin is -2133.4%, showing how much revenue survives after costs and taxes. EPS is $-0.38, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | May 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 27, 2026 |
How much revenue does SGMO generate?
Sangamo Therapeutics, Inc. (SGMO) reported $39.55M of revenue in fiscal 2025.
Is SGMO profitable?
Sangamo Therapeutics, Inc. (SGMO) reported -$122.93M of net income, with a net margin of -310.8%.
Continue the stock analysis
Jump to another research area for this company.